Single low-dose primaquine for malaria control in Africa: a systematic review of safety, efficacy and implementation barriers.

Since 2012, the WHO has recommended a single low dose of primaquine (SLDPQ, 0.25 mg/kg) alongside artemisinin-based combination therapies (ACTs) to block transmission and combat artemisinin resistance. Despite its proven benefits, SLDPQ adoption in African malaria policies remains limited.

Prevalence of Plasmodium falciparum parasites harbouring chloroquine-resistant but not artemisinin-resistant alleles in Busia County, Western Kenya.

Background: The recent emergence of Plasmodium falciparum parasites harbouring kelch 13 mutations associated with artemisinin partial resistance (ART-R) in sub-Saharan Africa is a major concern. Regular molecular epidemiological surveys are recommended to monitor the level of mutant parasites associated with drug resistance.

Objective: To analyse single nucleotide polymorphisms (SNPs) in P.

High Prevalence of Artemisinin-Resistant Plasmodium falciparum, Southeastern Sudan.

We conducted a hospital-based cross-sectional study of Plasmodium falciparum in 2017 in southeastern Sudan. Among 257 P. falciparum samples, we found 22% harbored the pfkelch13 R622I mutation and 10.

Monitoring molecular markers associated with antimalarial drug resistance in south-east Senegal from 2021 to 2023.

Background: Since 2006, artemisinin-based combination therapies (ACTs) have been introduced in Senegal in response to chloroquine resistance (CQ-R) and have shown high efficacy against Plasmodium falciparum. However, the detection of the PfKelch13R515K mutation in Kaolack, which confers artemisinin resistance in vitro, highlights the urgency of strengthening antimalarial drug surveillance to achieve malaria elimination by 2030.

Objective: To assess the proportion of P.